The mRNA Covid-19 vaccine by Gennova Biopharmaceuticals will hopefully not solely obtain an analogous efficacy to the candidates developed by Pfizer and Moderna, however may also be extra affordably priced for a rustic like India, in response to CEO Dr Sanjay Singh.
Our vaccine will work similarly to Pfizer’s and Moderna’s candidates. Regardless of the truth that that is primarily based on the self-amplifying mRNA platform, it permits you to give the message to the cells, which converts it into the antigen, producing a neutralising immune response towards the Covid-19 virus. Unlike ours, Moderna’s and Pfizer’s vaccines use non-replicating mRNA.
A self-amplifying kind mRNA is way more helpful in such a pandemic state of affairs, the place the vaccine deployment is just not in hundreds of thousands, however billions. For the nation’s inhabitants, this would be the most acceptable vaccine candidate. The benefit is which you can give perhaps a decrease dose of the vaccine.
Moderna’s vaccine is reported to work at 100 micrograms in two doses, whereas Pfizer’s works at 30 micrograms in two doses. We are concentrating on 5, 10 and 25 micrograms and we hope that anyone of those doses will show to be efficacious.
